terça-feira, 6 de outubro de 2026
PesquisarExplore
Via News Knowledge File

Apple Inc.

organization80% conf.·synced Oct 6, 2026

Technology company producing consumer electronics and software

60
sourced metrics
2073
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week Low
245.27USD
Oct 5, 2026reference only
Stock Price
332.89USD
Oct 5, 2026reference only
Market Cap
4858256580200USD
Oct 5, 2026reference only
Price 52 Week High
341.07USD
Oct 5, 2026reference only
Stock Return Ytd
22.8%
Oct 5, 2026reference only
Shares Outstanding
14594180000.0shares
Jul 17, 2026reference only
Net Income
29789000000.0USD
Jun 27, 2026reference only
Stockholders Equity
107520000000.0USD
Jun 27, 2026reference only
Total Liabilities
275746000000.0USD
Jun 27, 2026reference only
Gross Profit
54770000000.0USD
Jun 27, 2026reference only
Eps
2.02USD_per_share
Jun 27, 2026reference only
Revenue
109417000000.0USD
Jun 27, 2026reference only
Cost Of Revenue
54647000000.0USD
Jun 27, 2026reference only
Cash
39544000000.0USD
Jun 27, 2026reference only
Total Assets
383266000000.0USD
Jun 27, 2026reference only
Operating Income
35695000000.0USD
Jun 27, 2026reference only
Rd Expense
11729000000.0USD
Jun 27, 2026reference only
Operating Cash Flow
53925000000.0USD
Dec 27, 2025reference only

Stated objectives

Expand facilities and teams across 8 US states over four years

source
target: 8 states with 20,000 new hires by 2029-01-01 00:00:00stated

Additional US R&D investment in AI and silicon engineering for semiconductors

source
stated

Manufacture Apple's proprietary chips exclusively in Arizona at TSMC Fab 21

source
stated

Shift to making key iPhone components internally

source
stated

Invest $600 billion over four years to bring manufacturing to U.S., supporting 450,000 supplier jobs and hiring 20,000 employees

source
target: 600 billion USD investment, 20,000 new hires by 2029-01-01 00:00:00stated

Double-digit year-over-year iPhone sales growth for December quarter (Q1 FY2026)

source
target: double_digit_growth by 2025-12-01 00:00:00stated

December quarter revenue to be best ever for company and iPhone

source
target: Record revenue by 2025-12-31 00:00:00stated

Release advanced AI features and launch AI wearable devices including glasses, pendant, and AirPods built around Siri

source
stated

Invest $600 billion in U.S. manufacturing through the American Manufacturing Program

source
target: 600 billion USD stated

Diversify production beyond China

source
stated

Relationship graph · 2073 connections

Developed by
820
Competes with
256
Covered by
158
Supplies to
146
Employs
144
Invested in
75
Customer of
73
headquartered in
47

Where sources disagree

We surface conflicts between sources rather than hiding them.

timing conflictunresolved

The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com